All In Biotech

Drug Trial Radar · NCT07445295

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

A Phase III Study of Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 558 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

558

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Jun 30, 2028

Study completion Nov 30, 2028

Sponsor

Lead sponsor
Chipscreen Biosciences, Ltd.Industry
Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III, multi-center study to evaluate the efficacy and safety of chiauranib plus plus toripalimab, albumin-paclitaxel and gemcitabine as first-line therapy in patients with metastatic pancreatic ductal adenocarcinoma. The study includes two period: Run-in period and Randomized controlled period. The Run-in period is a single-arm, open-label study enrolling approximately 20 participants, who received the combination therapy of chiauranib plus toripalimab, albumin-paclitaxel and gemcitabine. The Randomized controlled period is a randomized, double-blind, parallel-controlled study enrolling approximately 538 participants, who are 1:1 randomly assigned to the experimental arm(chiauranib plus Toripalimab, albumin-paclitaxel and gemcitabine) or the control arm (Chiauranib placebo plus toripalimab placebo, albumin-paclitaxel and gemcitabine).

Conditions

  • Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • ChiauranibDrug

    50 mg, oral administration once daily

  • Toripalimab InjectionDrug

    3mg/kg, maximum dose 240mg, administered intravenously on Days 1 and 15 of each 28-day cycle

  • Albumin-paclitaxel InjectionDrug

    125 mg/m\^2, administered intravenously on Days 1, 8 and 15 of each 28-day cycle

  • Gemcitabine InjectionDrug

    1000 mg/m\^2, administered intravenously on Days 1, 8 and 15 of each 28-day cycle

  • Chiauranib placeboDrug

    50 mg, oral administration once daily

  • Toripalimab Injection placeboDrug

    3mg/kg, maximum dose 240mg, administered intravenously on Days 1 and 15 of each 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse eventsTime frame: Run-in period.From the enrollment until 28 days after the last dose
  2. OSTime frame: Randomized controlled period. From the first dose to death or end of study, an average of 2 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.